Higa, Shingo http://orcid.org/0000-0002-9430-7809
Nozawa, Kazutaka
Karasawa, Yusuke
Shirai, Chikako
Matsuyama, Satoshi
Yamamoto, Yuji
Laurent, Thomas
Asami, Yuko
Funding for this research was provided by:
Viatris Pharmaceuticals Japan Inc., Tokyo, Japan.
Article History
Accepted: 15 May 2022
First Online: 2 July 2022
Declarations
:
: This work was sponsored and funded by Viatris Pharmaceuticals Japan Inc., Tokyo, Japan. The medical writing was supported by Robert Phillips at Clinical Study Support, Inc., Nagoya, Japan and funded by Viatris Pharmaceuticals Japan Inc.
: The authors declare the following financial interests/personal relationships. SH, KN, YK, CS, SM, and YA are employees of Viatris Pharmaceuticals Japan Inc., Tokyo, Japan. TL is an employee of Clinical Study Support, Inc., Nagoya, Japan and was involved in the study under contract with Viatris Pharmaceuticals Japan Inc. YY is the President of MinaCare Co., Ltd., Tokyo, Japan that received fees for data usage from Viatris Pharmaceuticals Japan Inc.
: The study was conducted in accordance with legal and regulatory requirements, including data protection laws. It used data obtained in an anonymized format and containing no personal information. Therefore, informed consent and ethics committee approval were not required because studies using only anonymized data are outside the scope of the Japanese Government’s “Ethical Guidelines for Medical and Health Research Involving Human Subjects.”
: Not applicable.
: Not applicable.
: The MinaCare data are proprietary to MinaCare, Co., Ltd. and not publicly available for research purposes. Researchers who would like to access the data for research purposes should contact Dr. Yuji Yamamoto (mc_info@minacare.co.jp) to make a data use agreement and pay a data availability fee.
: Not applicable.
: All authors made substantial contributions to all of the following: (1) the conception and design of the study, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted and meeting the ICMJE authorship criteria.